Lunai Bioworks Inc (LNAI) Stock Price, Quote & News

Company Profile

Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States and the Netherlands. It operates through three segments, RENB, BioSymetrics, and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer. It also develops an artificial intelligence platform...

Industry: Biotechnology

Sector: Healthcare

Phone: 305 918 1980

Website: www.lunaibioworks.com

Address:

2080 Century Park East, Suite 906, Los Angeles, United States

focafoca99 Feb. 23 at 9:54 PM

$LNAI hearing panel officially scheduled on March 26.

0 · Reply

Stengaard1 Feb. 23 at 9:49 PM

$LNAI the stay until March 26th has just been confirmed… https://ir.lunaibioworks.com/financials/sec-filings/sec-filings-details/default.aspx?FilingId=19174853 In order words -LNAI has to start delivering on the promises Mede in the Shareholder letter

0 · Reply

Stengaard1 Feb. 23 at 9:10 PM

$LNAI It would be interesting what Weinstein hoped to achieve with the upbeat shareholder letter 🤔🤔 if it was meant to make the shareholders feel better then he obviously has not suceeded.

1 · Reply

11thestate Feb. 23 at 1:12 PM

$ENOB (now $LNAI ) investors — there’s no hidden secret here. Just one thing you really need to know. Here’s how to handle your losses. More importantly, how to either recover them or risk losing even more: https://11th.com/cases/enochian-biosciences-investor-settlement

0 · Reply

BillionerOfKing Feb. 22 at 8:15 PM

$LNAI Current Stock Price: $0.55 Contracts to trade: $2.5 LNAI Mar 20 2026 Call Entry: $0.05 Exit: $0.08 ROI: 80% Hold ~21 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Nottrue Feb. 20 at 9:15 PM

$LNAI all crooks at the top

0 · Reply

MarketForecasting Feb. 20 at 8:24 PM

$LNAI A fake company , short it to zero…

0 · Reply

Stengaard1 Feb. 19 at 7:59 PM

$LNAI I am not saying that LNAI has the holy grail for Alzheimers disease - but bloodbased test is going to revolutionise the way we diagnose the various (yes there are more than just a few) subtypes of Alzheimer's . Understanding that there is not a "one-size-fits-all", and that each subtype requires different treatment is paramount. LNAI will not be curing Alzheimer's but they could hold the key to diagnosing it right https://x.com/LillyNeuroInt/status/2023698942160994484?s=20

1 · Reply

BreakoutPika Feb. 19 at 5:42 PM

$YAAS $RAYA $LNAI $ORKT ÷

0 · Reply

Stengaard1 Feb. 19 at 3:06 PM

$LNAI The new patent, a very short explanation: The patent issued to Lunai Bioworks is legal proof that their special kind of medical‑AI “engine” belongs to them. If what LNAI says is true - then "Lunai- AI" can tell detailed differences between diseases, helping scientists and doctors treat people more accurately. Specifically Lunai Bioworks’ PR says the company has been granted a U.S. patent covering the core architecture of its biomedical AI platform. The key technical and business takeaway is that this patent legally protects the computational framework their AI uses to analyze biological datasets and identify highly precise “disease subtypes.” This is not a patent on a new drug or on lab work — it’s on how their AI system works internally: – the algorithms, data‑flow, and learning structure that generate its insights. I have no clue what it means in terms of revenue... but I think it it a way to safeguard findings/mechanisms for future use

0 · Reply

Lunai Bioworks (NASDAQ: LNAI) Locks Down Core AI Architecture with U.S. Patent Enabling Precision Disease Subtyping

Feb 13, 2026, 8:31 AM EST - 10 days ago

Lunai Bioworks (NASDAQ: LNAI) Highlights Drug Discovery and Biodefense AI Platform on CNBC

Feb 9, 2026, 9:15 AM EST - 14 days ago

Lunai Bioworks (NASDAQ: LNAI) Launches AI Oncology Pilot with Clinical-Stage Partner to Analyze Randomized Phase 2 Metastatic Colorectal Cancer Survival Trial Data

Jan 27, 2026, 10:36 AM EST - 27 days ago

Lunai Bioworks (NASDAQ: LNAI) Launches Sentinel, an AI Safeguard to Block Large Language Models from Generating Novel Chemical Weapons

Jan 26, 2026, 9:30 AM EST - 4 weeks ago

Lunai Bioworks (NASDAQ: LNAI) Expands NIH-Funded AI Program into Commercial Alcohol Use Disorder Drug Discovery

Dec 18, 2025, 9:00 AM EST - 2 months ago

Lunai Bioworks (NASDAQ: LNAI) Featured in International Business Times as AI Partnership Talks Advance

Dec 9, 2025, 7:45 AM EST - 2 months ago

Lunai Bioworks Identifies Three Parkinson's Subtypes and Prioritized Drug Targets to Accelerate Proof-of-Concept Programs and Strategic Partnerships in a $13B Market

Nov 25, 2025, 7:45 AM EST - 3 months ago

Lunai Bioworks Secures First Licensing LOI Following Landmark Breakthrough Showing Complete Tumor Regression in Humanized Cancer Models

Nov 5, 2025, 9:22 AM EST - 3 months ago

Lunai Bioworks achieves complete regression of both primary and metastatic pancreatic tumors in preclinical humanized models, marking a breakthrough in allogeneic cancer immunotherapy

Oct 30, 2025, 9:32 AM EDT - 4 months ago

Lunai Bioworks Harnesses AI and Zebrafish Data to Advance Early Detection of Neurotoxic Compounds

Oct 16, 2025, 9:45 AM EDT - 4 months ago

Landmark Study Identifies Prognostic Biomarkers in Duchenne Muscular Dystrophy Using Large-Scale Serum Proteomics

Oct 16, 2025, 9:15 AM EDT - 4 months ago

Lunai Bioworks Regains Compliance with Nasdaq Minimum Bid Price Requirement

Oct 6, 2025, 9:15 AM EDT - 5 months ago

Lunai Bioworks Launches AI-Powered Alzheimer's Disease Program, Expanding Neurodegenerative Pipeline

Sep 30, 2025, 9:15 AM EDT - 5 months ago

Lunai Bioworks Unveils New Corporate Identity, Streamlined Capital Structure, and Strategic Focus on AI-Powered Therapeutics and Biodefense

Sep 25, 2025, 8:30 AM EDT - 5 months ago

Lunai Bioworks Advances Biomarker Discovery Preclinical Program in Parkinson's Disease, Positioning for Strategic Pharma Partnerships

Sep 24, 2025, 4:50 PM EDT - 5 months ago

Lunai Bioworks, Inc. to Effect 10:1 Reverse Stock Split

Sep 11, 2025, 7:00 AM EDT - 5 months ago

Lunai Bioworks subsidiary BioSymetrics and Brigham and Women's Hospital Awarded NIH STTR Grant to Develop AI-Powered Platform for Alcohol Use Disorder Therapeutics

Sep 9, 2025, 9:12 AM EDT - 5 months ago

Top 3 Health Care Stocks You'll Regret Missing In Q3

SMMT

Sep 9, 2025, 8:47 AM EDT - 5 months ago

Lunai Bioworks Inc. Unveils Transformer Platform to Secure Generative AI and Accelerate Drug Discovery

Sep 8, 2025, 8:50 AM EDT - 6 months ago

Lunai Bioworks Strengthens European Strategy Through Restructuring

Sep 4, 2025, 10:05 AM EDT - 6 months ago

Lunai Bioworks Inc. Retains American Defense International

Aug 27, 2025, 9:45 AM EDT - 6 months ago

Renovaro Inc. Announces Corporate Name Change to Lunai Bioworks, Inc., Reflecting Strategic Focus on AI-Driven Biodefense, Drug Discovery and Advanced Diagnostics

Aug 8, 2025, 10:45 AM EDT - 7 months ago

Renovaro Inc. (NASDAQ: RENB) Mentioned in RealClearDefense Article on AI and Biodefense Risks

Jul 28, 2025, 10:38 AM EDT - 7 months ago

Renovaro Secures Key AI Patents, Strengthening Market Position in $20B Biomedical AI Sector

Jul 17, 2025, 9:15 AM EDT - 7 months ago

Peer-Reviewed Study Validates Renovaro's Genetically Engineered Dendritic Cell Therapy with Potent Anti-Tumor Efficacy

Jul 9, 2025, 8:00 AM EDT - 8 months ago

Renovaro Strengthens Balance Sheet Through Debt Conversion and Advances AI-Driven Initiatives

Jun 30, 2025, 9:21 AM EDT - 8 months ago

Renovaro Launches AI-Based Neurotoxin Countermeasure Initiative Addressing Emerging National Security Needs

Jun 3, 2025, 9:15 AM EDT - 9 months ago

Renovaro Secures Key U.S. Patent to Strengthen AI-Driven Drug Discovery and Diagnostics Platform

May 22, 2025, 3:12 PM EDT - 9 months ago

UPDATE - Renovaro Inc. Announces Expedited Trial for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology

May 22, 2025, 11:05 AM EDT - 9 months ago

Renovaro Inc. Announces Expedited Trail for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology

May 14, 2025, 9:15 AM EDT - 10 months ago

Renovaro Launches Augusta, an AI-Powered Precision Neurology Platform

May 13, 2025, 9:15 AM EDT - 10 months ago

Renovaro and Amsterdam University Medical Center Announce Exclusive Collaboration to Advance Blood Platelet RNA Diagnostics

Apr 22, 2025, 9:20 AM EDT - 10 months ago

Renovaro Secures High-Powered Computing from Nebul Through a Partnership to Accelerate Next-Generation Biomarker Discovery and Diagnostic Programs

Apr 9, 2025, 9:25 AM EDT - 11 months ago

Renovaro and BioSymetrics Close Merger to Accelerate AI-Driven Biomarker Discovery and Precision Medicine

Apr 4, 2025, 9:40 AM EDT - 11 months ago

Renovaro Provides Update to Definitive Agreement with Predictive Oncology

Mar 3, 2025, 9:15 AM EST - 1 year ago

Renovaro Completes First Milestone Payment to Finalize Definitive Agreement with Predictive Oncology

Feb 26, 2025, 1:25 PM EST - 1 year ago

Renovaro and BioSymetrics Announce Definitive Merger Agreement to Advance AI-Driven Biomarker Discovery and Precision Medicine

Feb 26, 2025, 9:15 AM EST - 1 year ago

Renovaro Announces $15 million in Equity Committed

Jan 7, 2025, 6:51 PM EST - 1 year ago

PREDICTIVE ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Predictive Oncology Inc. - POAI

AGPU

Jan 7, 2025, 9:15 AM EST - 1 year ago

Renovaro Appoints Nathen Fuentes as Chief Financial Officer

Jan 7, 2025, 9:15 AM EST - 1 year ago

Renovaro Issues Shareholder Letter and Provides Corporate Update

Jan 6, 2025, 9:15 AM EST - 1 year ago

Renovaro to Acquire Predictive Oncology in All-Stock Transaction

Dec 30, 2024, 9:00 AM EST - 1 year ago

Renovaro Inc. Appoints Maurice van Tilburg to Lead GEDi Cube BV

Dec 23, 2024, 9:00 AM EST - 1 year ago

RenovaroCube Receives Approval of Lumina Project by the Eurostars Funding Program

Dec 20, 2024, 3:40 PM EST - 1 year ago

Renovaro Regains Compliance with NASDAQ Listing Requirement

Dec 20, 2024, 9:00 AM EST - 1 year ago

Renovaro Enters into a Strategic Collaboration with Nebul to Advance a Paradigm Shift for Early Disease Detection

Oct 17, 2024, 9:15 AM EDT - 1 year ago

RenovaroCube Presents Novel Insights on Non-Invasive Cancer Diagnostics Using Oxford Nanopore Sequencing

Oct 16, 2024, 9:28 AM EDT - 1 year ago

Renovaro Announces Strategic Restructuring and Leadership Transition

Sep 13, 2024, 9:00 AM EDT - 1 year ago

RenovaroCube to Present Cutting-Edge Cancer Diagnostics Research at European Society for Medical Oncology Congress

Sep 11, 2024, 9:15 AM EDT - 1 year ago

RenovaroCube Announces Strategic Offering of Up to 20% Ownership

focafoca99 Feb. 23 at 9:54 PM

$LNAI hearing panel officially scheduled on March 26.

0 · Reply

Stengaard1 Feb. 23 at 9:49 PM

0 · Reply

Stengaard1 Feb. 23 at 9:10 PM

$LNAI It would be interesting what Weinstein hoped to achieve with the upbeat shareholder letter 🤔🤔 if it was meant to make the shareholders feel better then he obviously has not suceeded.

1 · Reply

11thestate Feb. 23 at 1:12 PM

0 · Reply

BillionerOfKing Feb. 22 at 8:15 PM

0 · Reply

Nottrue Feb. 20 at 9:15 PM

$LNAI all crooks at the top

0 · Reply

MarketForecasting Feb. 20 at 8:24 PM

$LNAI A fake company , short it to zero…

0 · Reply

Stengaard1 Feb. 19 at 7:59 PM

1 · Reply

BreakoutPika Feb. 19 at 5:42 PM

$YAAS $RAYA $LNAI $ORKT ÷

0 · Reply

Stengaard1 Feb. 19 at 3:06 PM

0 · Reply

Stengaard1 Feb. 19 at 2:19 PM

$LNAI building up an interesting patent-portfolio ..https://ir.lunaibioworks.com/news/news-details/2026/Lunai-Bioworks-NASDAQ-LNAI-Locks-Down-Core-AI-Architecture-with-U-S--Patent-Enabling-Precision-Disease-Subtyping/default.aspx

0 · Reply

Dizzy8 Feb. 19 at 12:24 PM

$LNAI It shall go above 1$ Soon. Oh Yes, mark my words.

0 · Reply

PikaPlays Feb. 18 at 12:48 PM

$RAYA $LNAI $ORKT $CETX

0 · Reply

MarketForecasting Feb. 17 at 10:01 PM

$LNAI no amount of gibberish nonsense can make me believe this won’t be delisted , it will , it definitely will . I truly believe that , real companies don’t get put in a delisting position to begin with

2 · Reply

stockinvestbull Feb. 17 at 9:33 PM

$LNAI Today's news (February 17, 2026) Highlights: - The company reported a strong financial turnaround, moving from a large loss last year to a $1.02 million net profit. - Operating expenses dropped sharply, mainly due to the absence of prior impairment charges. - Promising new cancer therapy platforms are under development (RENB‑DC11, RENB‑DC20). - Improved cash management resulted in lower operating cash outflow, signaling better operational efficiency. https://www.tradingview.com/news/tradingview:3d56a1c979cde:0-lunai-bioworks-inc-sec-10-q-report/

0 · Reply

Stengaard1 Feb. 17 at 9:31 PM

$LNAI quarterly report out: https://ir.lunaibioworks.com/financials/sec-filings/sec-filings-details/default.aspx?FilingId=19154115

0 · Reply

BreakoutPika Feb. 17 at 6:28 PM

$RAYA $LNAI $ORKT $LESL =

0 · Reply

Stengaard1 Feb. 17 at 4:03 PM

$LNAI $LNAI when you read the 8-K about deficiency it says the following: "The Company has filed a request for a hearing before the Nasdaq Hearings Panel to appeal Nasdaq staff’s determination. A timely hearing request will stay the suspension of the Company’s securities and the filing of the Form 25 pending the outcome of the hearing. There can be no assurance that the appeal will be successful." I reached out to a friend who knows a bit about the procedures , and asked about the new rules. He said that a stay was almost always given automatically for 45 days. So, it is my opinion that LNAI will be getting a stay (or perhaps even have already gotten astay) - and that the company is also listed tomorrow and the days after :) It is my understanding that the company did appeal, and I would expect that the appeal was granted otherwise they should have sent out a 8-K/delisting note today - I have not heard anything from LNAI; which comes as no surprise (unfortunately)

2 · Reply

MarketForecasting Feb. 17 at 2:35 PM

$LNAI Delistment Forthcoming

0 · Reply

CapitalProvenance Feb. 17 at 1:32 PM

$LNAI Obscure micro-cap; minimal information.

0 · Reply

MarketForecasting Feb. 13 at 8:25 PM

$LNAI 🥹😳

0 · Reply

MarketForecasting Feb. 13 at 3:05 PM

$LNAI a lot of you will be trading this on OTC , I held firm that this was an easy short opportunity

2 · Reply

Market Cap	13.19M
Revenue (ttm)	0.00
Net Income (ttm)	-178.01M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	243,700
Avg Vol	255,192
Day's Range	N/A - N/A
Shares Out	24.19M
Stochastic %K	4%
Beta	0.46
Analysts	Strong Buy
Price Target	N/A